window.dataLayer = window.dataLayer || []; (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= ''+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-5L46PPF2');

Satellite Symposia

Sunday, 18 June 2017
Satellite Symposium (SAT 1)
Hall 3a, 17:30 – 19:00
The future of urticaria – advances in CSU research

Chair: Marcus Maurer, Germany

Introduction: Welcome address
Marcus Maurer, Germany

Under the skin of CSU – diagnostic and prognostic biomarkers in urticaria
Martin Metz, Germany

Keeping it real: a look at the latest real-world data in CSU management
Alexander Marsland, United Kingdom

Managing relapse in CSU
Gordon Sussman, Canada

Looking beyond CSU – a round-up of recent research
Marcus Maurer, Germany

Questions from the audience
All speakers

Closing address
Marcus Maurer, Germany

Company Sponsored Satellite Symposium (SAT 2)
Hall 3c, 17:30 – 19:00

A New Perspective in the Treatment of Allergies in Adults and Children: Bilastine

Chairs: Marysia Recto, Philippines & Torsten Zuberbier, Germany

Allergic Rhinitis guidelines: the seek for the Ideal Antihistamine
Piotr Kuna, Poland

The world of Urticaria: guidelines update and new evidences for Bilastine
Torsten Zuberbier, Germany

Bilastine in childhood: a new effective and safe solution for Paediatricians
Zoltán Novak, Hungary

Company Sponsored Satellite Symposium (SAT 3)
Shire International GmbH
Hall 3d, 17:30 – 19:00

Hereditary angioedema: what does the future hold?

Co-chairs: Marco Cicardi, Italy & Markus Magerl, Germany
Faculty: Emel Aygören-Pürsün, Germany

Welcome, and an introduction to hereditary angioedema (HAE)
Marco Cicardi, Italy

Challenges and current treatment options in the management of paediatric HAE patients
Markus Magerl, Germany

Future therapeutic options for the management of paediatric HAE patients
Emel Aygören-Pürsün, Germany

The future of HAE treatment: innovative therapies to address unmet needs
Marco Cicardi, Italy

Q&A and closing remarks
All faculty/co-chairs

Company Sponsored Satellite Symposium (SAT 4)
Hall 3e, 17:30 – 19:00

The Asthma Journey – Right Road, Right Destination

Chair: Maritta Kilpeläinen, Finland

The building blocks for optimal asthma treatment
Maritta Kilpeläinen, Finland

Laying the foundations for improvements in therapy: Shared decision-making
Neil Martin, United Kingdom

Drawing the blueprints for correct asthma diagnosis
Peter Howarth, United Kingdom

Raising outcomes in the treatment of severe eosinophilic asthma
Neil Barnes, GSK, United Kingdom

Surveying the evidence: Effectiveness of targeted therapies in the real world
Andreas Heddini, United Kingdom

Q&A and symposium close
Maritta Kilpeläinen, Finland; Neil Barnes, United Kingdom

Company Sponsored Satellite Symposium (SAT 5)
Allergy Therapeutics plc.
Hall 3g, 17:30 – 19:00
The Best Therapies By Design

The importance of defining the optimal dose
Jörg Kleine-Tebbe, Germany

Molecular fingerprinting of complex allergoids
Erika Jensen-Jarolim, Austria

Rationale for broad spectrum grass immunotherapy
Uwe E. Berger, Austria

Defining the plateau of the efficacy for Allergen Specific Immunotherapy
Tim Higenbottam, United Kingdom

Company Sponsored Satellite Symposium (SAT 6)
Nestlé Health Science
Room 101, 17:30 – 19:00

Controversies on Special Products for Managing Cow’s Milk Protein Allergy (CMPA) in Infants – Safety and Suitability   Session Webcast icon

Chairpersons: Antonella Muraro, Italy & Arne Høst, Denmark

Choosing the most appropriate dietary management for infant with CMPA
Rosan Meyer, United Kingdom

Not all extensively hydrolysed formulas intended for CMPA are the same
Martinas Kuslys, Switzerland

New guidelines ensuring safe products for infants with CMPA – update from the EAACI Task Force on special products for CMPA
Antonella Muraro, Italy
Arne Høst, Denmark

Monday, 19 June 2017

Company Sponsored Satellite Symposium (SAT 7)
Hall 3a, 17:45 – 19:15

A Personalized Approach to Eosinophilic Asthma: Expert Perspectives in Clinical Practice

Welcome and Introductions
Ian Pavord, United Kingdom

Challenges in Asthma Heterogeneity
Leif Bjermer, Sweden

Clinical and Patient Perspectives in Severe Eosinophilic Asthma
Arnaud Bourdin, France

The Evolving Science of Severe Asthma and Emerging Clinical Practices
Ian Pavord, United Kingdom

Panel Discussion and Audience Q&A

Company Sponsored Satellite Symposium (SAT 8)
DBV Technologies
Hall 3d, 17:45 – 19:15

Investigational Epicutaneous Immunotherapy: Shaping the Future of Treating Food Allergies

Chair: Jonathan Hourihane, Ireland

Welcome and Introductions
Jonathan Hourihane, Ireland

The Unique Immune Properties of the Skin
Hugh A. Sampson, United States

Clinical Development of EPIT in Food Allergies
André C. Knulst, The Netherlands

What Are the Expectations for Peanut Allergy Immunotherapy?
Jonathan M. Spergel, United States

Conclusions and Faculty Panel Discussion

Company Sponsored Satellite Symposium (SAT 9)
CSL Behring GmbH
Hall 3e, 17:45 – 19:15

The dawn of a new era of HAE Management Session Webcast icon

Chairs: Marco Cicardi, Italy
Timothy Craig, United States

Welcome and introduction
Marco Cicardi, Italy; Timothy Craig, United States

Unmet medical needs in HAE management
Markus Magerl, Germany

Experience with C1-INH replacement therapy for HAE management
Hilary Longhurst, United Kingdom

COMPACT: Evidence for subcutaneous C1-INH for routine prevention
Bruce Zuraw, United States

Panel discussion

Closing remarks
Marco Cicardi, Italy; Timothy Craig, United States

Company Sponsored Satellite Symposium (SAT 10)
Sanofi Genzyme and Regeneron
Room 103a, 17:45 – 19:15

Evolving Concepts and Clinical Implications for Targeted Therapeutics in Asthma Patients with Overlapping Type 2 Comorbidities Session Webcast icon

Chair: William Busse, United States

Welcome and Introduction
William Busse, United States

Clinical Insights into the Management of Patients with Multiple Comorbidities: Clinical Challenges, Best Practices, and Future Directions
William Busse, United States

High Burden of Disease in Patients with Multiple Type 2 Diseases and Associated Comorbidities
David Price, United Kingdom

Lessons Learned from Immune-Epithelial Interactions in the Skin and Implications for Airway Diseases
Donald Leung, United States

Exploring the Links Between Upper and Lower Airway Inflammation and Implications for The Clinic
Claus Bachert, Belgium

Asthma Immunology – A clinical approach
Klaus Rabe, Germany

Closing Remarks and Panel Q&A
William Busse

Company Sponsored Satellite Symposium (SAT 11)
Teva Pharmaceuticals
Room 102, 17:45 – 19:15

Personalising clinical management in severe asthma

Chair: Vibeke Backer, Denmark

Welcome and introduction
Vibeke Backer, Denmark

Severe asthma: idetifying those with the eosinophilic phenotype
Dave Singh, United Kingdom

What biomarkers are clinically important in the inflamed lung?
Christian Virchow, Germany

Anti-IL-5 therapy: from clinical trials to clinical practice
Guy Brusselle, Belgium

Summary and close
Vibeke Backer, Denmark

Tuesday, 20 June 2017

Company Sponsored Satellite Symposium (SAT 12)
Aimmune Therapeutics, Inc
Hall 3a, 17:30 – 19:00

Meeting Patients’ Needs: Exploring a Path to an Approved Oral Treatment for Peanut Allergy Session Webcast icon

Chair: Clare Mills, United Kingdom

Chair’s address
Clare Mills, United Kingdom

Why do patients and families need an approved oral therapy for peanut allergy?
Sabine Schnadt, Germany

How is oral immunotherapy evolving?
Kirsten Beyer, Germany

Defining success of oral immunotherapy for Health Care Practitioners
Pablo Rodriguez del Rio, Spain

Chair’s closing remarks

Company Sponsored Satellite Symposium (SAT 13)
Sanofi Genzyme and Regeneron
Hall 3g, 17:30 – 19:00

Advancing the Clinical Care of Patients With Persistent Atopic Dermatitis

Chair: Thomas Bieber, Germany

Welcome and Introduction
Thomas Bieber, Germany

Clinical Challenges, Best Practices, and Future Directions
Thomas Bieber, Germany

The Predisposition of Patients Living With AD: Comorbidities and Atopic March
Mark Boguniewicz, United States

Emerging Therapeutic Strategies for Atopic Dermatitis
Michael J. Cork, United Kingdom

Looking Forward – Defining Different AD Clinical Phenotypes: Biomarkers and Genotypes Associated With AD Endotypes
Thomas Bieber, Germany

Closing Remarks and Panel Q&A
Thomas Bieber, Germany

Company Sponsored Satellite Symposium (SAT 14)
Room 103a, 17:30 – 19:00

Peptide carrier fusion vaccines: A new paradigm for allergen specific immunotherapy

Chairpersons: Marianne van Hage, Sweden & Rudolf Valenta, Austria

Rainer Henning, Austria

Limitations of current allergen extract-based AIT
Marianne van Hage, Sweden

Design of recombinant AIT vaccines based on the peptide carrier fusion technology
Rudolf Valenta, Austria

Clinical evaluation of a grass pollen allergy vaccine based on the peptide carrier fusion technology
Petra Zieglmayer, Austria

Questions & Answer

Stay in touch

Want to get the news about all the EAACI events?
Subscribe for our events-newsletter here.